Analysis of Mexican young women with primary ovarian insufficiency induced by gynaecological and haematological cancer management

García-García, Marisol; Cantú-de-León, David; Salcedo‐Hernández, Rosa A.; González-Enciso, Aarón; Sepulveda-Rivera, Cintia Maria; Rodríguez, Julio César González; Barquet-Muñoz, Salim Abraham

doi:10.1080/01443615.2022.2112026

Cited by 1 publication

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The remaining publications were filtered through inclusion and exclusion criteria. Thirty studies were excluded as follows: eight studies [30][31][32][33][34][35][36][37] were conference papers, case reports or other reviews; six [38][39][40][41][42][43] did not concentrate on OC; six [44][45][46][47][48][49] did not asses OS, PFS or the effects of HRT; another six [50][51][52][53][54][55] did not provide a complete text; three publications [56][57][58] only evaluated the pre-diagnosis effect of HRT in OC; while one study [59] presented in-vitro results. Finally, 11 studies [15,[60][61][62][63][64][65][66][67][68][69] were included in the qualitative synthesis.…”

Section: Study Selectionmentioning

confidence: 99%

Impact of Hormone Replacement Therapy on the Overall Survival and Progression Free Survival of Ovarian Cancer Patients: A Systematic Review and Meta-Analysis

Achimaș-Cădariu

Păun

Pașca

2023

Cancers

View full text Add to dashboard Cite

Background: Frequently, patients treated for Ovarian Cancer (OC) undergo menopause with subsequent symptoms. This review scrutinised the impact of Hormone Replacement Therapy (HRT) on the Overall Survival (OS) and Progression-Free Survival (PFS) of patients diagnosed with OC. Methods: A systematic literature search was conducted in the most popular English databases. Inclusion and exclusion criteria were applied to select publications that evaluate OS and PFS in these patients. End-point analysis targeted values of log(HR) and its Standard Error (SE). Results: Up to 1 September 2022, 11 studies were included in the qualitative synthesis. Eight publications, totalling 4191 patients, were included in the meta-analyses. Eight studies were considered for the OS analysis and pooled an HR of 0.66 with respective 95% CI between 0.57 and 0.76, with a p-value < 0.00001 at a Z value of 5.7, in favour of the HRT group. Results for PFS showed an overall HR of 0.73 in favour of the HRT group; CI between 0.57 and 0.95, p = 0.02 at a Z value of 2.36. Further subgroup analyses highlighted the non-inferiority of this treatment. Conclusions: Patients treated for OC that receive HRT for menopausal symptoms after various treatments appeared to have better OS than never-users.

show abstract